

## P-glycoprotein: a clue to vitamin K antagonist stabilization

Liliane Gschwind<sup>1,2</sup>, Victoria Rollason<sup>1</sup>, Françoise Boehlen<sup>3</sup>, Michela Rebsamen<sup>4</sup>, Christophe Combescure<sup>5</sup>, Alain Matthey<sup>1</sup>, Pascal Bonnabry<sup>2,6</sup>, Pierre Dayer<sup>1</sup>, Jules A. Desmeules<sup>1</sup>

<sup>1</sup>*Division of Clinical Pharmacology & Toxicology, University Hospitals of Geneva*

<sup>2</sup>*School of Pharmaceutical Sciences, University of Geneva, University of Lausanne*

<sup>3</sup>*Division of Angiology & Haemostasis, University Hospitals of Geneva,*

<sup>4</sup>*Division of Laboratory Medicine, University Hospitals of Geneva,*

<sup>5</sup>*Division of Clinical Epidemiology, University Hospitals of Geneva,*

<sup>6</sup>*Pharmacy, University Hospitals of Geneva, Switzerland*

### Abstract

**Introduction:** Acenocoumarol is a vitamin K antagonist used in some European countries. As warfarin, this drug is characterized by a narrow therapeutic index and a large interindividual variability.

**Objective:** The objective of this study was to assess the involvement of *ABCB1* polymorphisms on acenocoumarol treatment.

**Method:** An observational cohort study was conducted to assess whether there is an association between the presence of the allelic variants of the *ABCB1* gene coding for P-glycoprotein and acenocoumarol stabilization and daily doses during the first 35 days of treatment.

**Results:** One hundred and fifteen patients met the inclusion criteria. The results of the clinical study showed that carriers of *ABCB1* c.3435TT were more rapidly stabilized than wild-type patients (HR: 2.97, 95% CI: 1.23–7.18;  $p = 0.02$ ). The same tendency was observed for the *ABCB1* c.2677GT and 2677TT genotypes compared with *ABCB1* c.2677GG. The *ABCB1* c.2677TT genotype was also associated with a significant increase in doses of acenocoumarol ( $p = 0.03$ ), the same tendency was observed with the *ABCB1* c.3435TT genotype compared with the wild-type patients.

**Conclusion:** These data suggest that *ABCB1* polymorphisms could be involved in the response to acenocoumarol treatment.

Published in: Pharmacogenomics. 2015;16:129-36.

doi: 10.2217/pgs.14.164.

Contact: [Liliane.Gschwind@hcuge.ch](mailto:Liliane.Gschwind@hcuge.ch)